Capital increase 2019
Below you find further information about the capital increase that was resolved by the Management Board of Epigenomics AG with approval of the Supervisory Board on October 17, 2019.
This website and the information contained therein do not constitute an offer to sell or a solicitation of an offer to buy any securities of Epigenomics AG in the United States of America (“U.S.”) or in any other jurisdiction or to any person if such offer or solicitation is unlawful or not authorized. Users of this website are requested to inform themselves about and to observe any such restrictions. The information set forth on this website must not be distributed in or to the U.S., to “U.S. persons” as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or to publications with a general circulation in the U.S. Each violation of such limitations may constitute a violation of applicable securities laws of the U.S. The shares of Epigenomics AG (the “Shares”) have not been and will not be registered under the Securities Act and may not be offered or sold in the U.S. unless pursuant to an exemption from registration requirements.
|Issue volume – Publication of Inside Information according to Article 17 MAR / November 7, 2019|
|Notification of issue volume
|Notification of subscription price / October 31, 2019|
|Subscription price – Publication of Inside Information according to Article 17 MAR / October 31, 2019|
|Securities Prospectus Capital Increase 2019|
|Publication of Inside Information according to Article 17 MAR / October 17, 2019|
|Subscription offer (Please note: Currently there is only a German version available)
For further information, please don’t hesitate to contact us:
Frederic Hilke (IR.on AG)
Tel: +49 221 9140-970